A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

While intensity didn’t appear to matter in this network meta-analysis, location did: in-person programs had the most impact.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

Following the recent IDE Approval by the U.S. Food and Drug Administration (FDA) for MagicTouch PTA, this enrolment heralds ...

A study comparing men and women suggests much of the association arises from genetic propensity to both conditions.

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

Greater transparency, monitoring, and regulatory oversight are needed around these transactions, a researcher says.

The ARIES-HM3 substudy may help persuade implanters who are less well-versed in the circulatory changes an LVAD affords.

An app-based program failed to boost function for most at 3 months, but positive signs were seen in women and after CABG.

The aim is to make it easier for consumers to determine how much saturated fat, sodium, and added sugar are inside.

The two-tiered classification focuses on preclinical and clinical stages of disease, and should help inform treatment ...